Chemokines as adjuvants of immune response
AssigneeSchering Corporation
InventorsChristophe Caux, Beatrice Vanbervliet, Carine Paturel, Alain Vicari, Giorgio Trinchieri, Francine Briere, Nathalie Bendriss
Life of this patent
Estimating the term…
Loading patent…
AssigneeSchering Corporation
InventorsChristophe Caux, Beatrice Vanbervliet, Carine Paturel, Alain Vicari, Giorgio Trinchieri, Francine Briere, Nathalie Bendriss
Estimating the term…
Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer, infectious diseases, autoimmune diseases, transplantation, and allergy by facilitating or inhibiting the migration or activation of a specific subset of antigen-presenting dendritic cells known as plasmacytoid dendritic cells (pDC). In particular, methods for treating disease states are provided comprising administration of chemokine receptor agonists and antagonists, alone or in combination with a disease-associated antigen, with or without an activating agent.
1-85. (canceled)
A method of treating a disease state comprising administering to an individual in need thereof an effective amount of a chemokine receptor antagonist sufficient to decrease migration of pDC, wherein the chemokine receptor antagonist is selected from the group consisting of a CXCR3 antagonist, a CXCR4 antagonist, a CCR6 antagonist, and a CCR10 antagonist, or a combination thereof.
(canceled)
Dependencies are inferred from the claim text.